Announcements Trials
Browse Landscape

Phase

Phase 2 48Phase 1 45Phase 1/2 19Phase 3 17Phase NA 13Phase EARLY_PHASE1 4Phase 4 2Phase 2/3 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 11Other hematologic neoplasm 8Genitourinary 8Gastrointestinal 7Plasma cell 6Dermatologic 5Head & Neck 4Myeloid 3Sarcoma 2Lymphoid 2Gynecologic 2Classical hematology 2Thoracic 1Other 1CNS 1

Conditions

Gastrointestinal Stromal Tumors 1Desmoid Tumors 1

Interventions

nirogacestat 1Imatinib Mesylate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Sarcoma × 30 days × Clear all
NCT01742299 2026-05-14

Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator

Novartis

Phase 4 Completed
155 enrolled
GastrointestinalSarcoma

Gastrointestinal Stromal Tumors

NCT07176689 2026-05-08

Nirogacestat in Premenopausal Females With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

Phase 4 Recruiting
50 enrolled
Sarcoma

Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡